ArticleFrontiers in medicine2024
Vascular ultrasound as a follow-up tool in patients with giant cell arteritis: a prospective observational cohort study.
Article in Frontiers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Dynamic vascular changes on long-term ultrasound monitoring predict relapse in large-vessel giant cell arteritis.Arthritis research & therapy · 2026Article
- Long-Term Follow-Up in Patients with Large-Vessel Vasculitis Applying Extracranial and Transcranial Duplex Sonography.Diagnostics (Basel, Switzerland) · 2026Article
- Imaging-guided stratification in giant cell arteritis: prognostic and therapeutic implications.Therapeutic advances in musculoskeletal disease · 2026Review
- Scoping review of clinical, laboratory, histopathological and imaging predictors of relapse in adults with biopsy- or temporal artery ultrasound-confirmed giant cell arteritis on standard therapy with glucocorticoids alone or in combination with biologics.Rheumatology advances in practice · 2026Review
- The Role of Imaging in Monitoring Large Vessel Vasculitis: A Comprehensive Review.Biomolecules · 2025Review
- Longitudinal changes on cranial magnetic resonance imaging in relapsing giant cell arteritis.Seminars in arthritis and rheumatism · 2025Article
- Treatment and risk of relapse in GCA in Western Norway 2013-2020: a retrospective cohort study.Rheumatology advances in practice · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To evaluate relapses in giant cell arteritis (GCA), investigate the utility of vascular ultrasound to detect relapses, and develop and assess a composite score for GCA disease activity (GCAS) based on clinical symptoms, ultrasound imaging activity, and C-reactive protein (CRP). Methods: Patients with GCA were prospectively followed with scheduled visits, including assessment for clinical relapse, protocol ultrasound examination, and CRP. At each visit, patients were defined as having ultrasound remission or relapse. GCAS was calculated at every visit. Results: The study included 132 patients, with a median follow-up time of 25 months [interquartile range (IR) 21]. The clinical relapse rate was 60.6%. There were no differences in relapse rates between GCA subtypes (cranial-GCA, large vessel (LV)-GCA, and mixed-GCA) ( Conclusion: We found moderate sensitivity and specificity for ultrasound as a monitoring tool for relapse in this prospective cohort of GCA patients. The extent or subtype of vasculitis at the diagnosis did not influence the number of relapses. Based on a combination of clinical symptoms, elevated CRP, and ultrasound findings, a composite score for GCA activity is proposed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.